Abstract: A composition for corrosion control in aqueous systems, the composition providing a formulation of a concentrated aluminum corrosion inhibitor; and (i) a polycarboxylic acid polymer, (ii) a sulfonic acid polymer, (iii) a combination of a polycarboxylic acid and a polysulfonic acid, (iv) an organic phosphonate, (v) a combination of a phosphonate and a polycarboxylic acid, or (vi) a combination of a phosphonate and a polysulfonic acid. A method for corrosion control in aqueous systems, the method providing a concentrated formulation, the concentrated formulation having an aluminum corrosion inhibitor and (i) a polycarboxylic acid polymer, (ii) a sulfonic acid polymer, (iii) a combination of a polycarboxylic acid and a polysulfonic acid, (iv) an organic phosphonate, (v) a combination of a phosphonate and a polycarboxylic acid, or (vi) a combination of a phosphonate and a polysulfonic acid; and delivering the concentrated formulation to an aqueous stream.

Abstract: The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.

Abstract: The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.

Abstract: The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.

Abstract: The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.

Abstract: The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.

Abstract: The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.

Abstract: The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.

Abstract: This invention provides a control release formulation or rumen-bypass dietary supplement in compacted form. The formulation or supplement has the capability to transport fatty acid calcium salt and between about 1-75 percent of one or more rumen-protected undegraded biologically active agents to the post-ruminal digestive system of a ruminant. A feedstock containing the formulation or supplement for ruminants beneficially improves feed efficiency and body growth. The feedstock also is adapted to improve the lactational performance of dairy cattle.

Abstract: This invention provides a control release formulation or rumen-bypass dietary supplement in compacted form. The formulation or supplement has the capability to transport fatty acid calcium salt and between about 1-75 percent of one or more rumen-protected undegraded biologically active agents to the post-ruminal digestive system of a ruminant. A feedstock containing the formulation or supplement for ruminants beneficially improves feed efficiency and body growth. The feedstock also is adapted to improve the lactational performance of dairy cattle.

Abstract: The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.

Abstract: This invention provides a control release formulation or rumen-bypass dietary supplement in compacted form. The formulation or supplement has the capability to transport fatty acid calcium salt and between about 1-75 percent of one or more rumen-protected undegraded biologically active agents to the post-ruminal digestive system of a ruminant. A feedstock containing the formulation or supplement for ruminants beneficially improves feed efficiency and body growth. The feedstock also is adapted to improve the lactational performance of dairy cattle.

Abstract: This invention provides a control release formulation or rumen-bypass dietary supplement in compacted form. The formulation or supplement has the capability to transport fatty acid calcium salt and between about 1-75 percent of one or more rumen-protected undegraded biologically active agents to the post-ruminal digestive system of a ruminant. A feedstock containing the formulation or supplement for ruminants beneficially improves feed efficiency and body growth. The feedstock also is adapted to improve the lactational performance of dairy cattle.

Abstract: A method of controlling the deposition of silica containing scales and their adhesion to surfaces in contact with an aqueous system is disclosed which comprises adding to the aqueous system about 1-500 ppm of a water-soluble or dispersible hydrophobically modified polyether polymer. Exemplary hydrophobically modified polyether polymers include alkylene oxide hydrophilic backbone repeat units and hydrophobic groups that may be attached to the backbone at a variety of locations such as 1) at the ends of the backbones, 2) either regularly or randomly spaced along the backbone length, or 3) as linking groups to link two or more portions of the backbone together.

Abstract: Acid mine demineralization methods wherein the acid mine drainage is neutralized, clarified, and forwarded to a microfiltration unit. The so filtered drainage water is then forwarded to a reverse osmosis unit. The permeate from the reverse osmosis unit is characterized by reduced sulfate, silica, calcium, aluminum, iron, magnesium, and manganese levels. Additionally, improvement in reduction of total dissolved solids is noted.

Abstract: A method of controlling the deposition of silica containing scales and their adhesion to surfaces in contact with an aqueous system is disclosed which comprises adding to the aqueous system a water-soluble or dispersible hydrophobically modified polyether polymer.

Abstract: Methods of enhancing performance of a semi-permeable filtration membrane such as a polyamide R.O. membrane. A water soluble polymer is brought into contact with the membrane structure and is characterized by the Formula I wherein E is a repeat unit remaining after polymerization of an ethylenically unsaturated monomer or mixtures thereof; R1 is hydrogen or C1-C4 alkyl; R2 is C1-C6 alkyl, C1-C6 alkylene, di-hydroxy substituted C1-C6 alkyl, di-hydroxy substituted C1-C6 alkylene, aryl, or mixtures thereof; n is 0 to about 100; R3 is OH, SO3Z OSO3Z, PO3Z2, OPO3Z2, CO2Z, or mixtures thereof; Z is hydrogen or a water-soluble cation; and the mole ratio c:d ranges from about 30:1 to 1:20 respectively.